financetom
Business
financetom
/
Business
/
Birkenstock's fourth-quarter revenue beats on resilient demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Birkenstock's fourth-quarter revenue beats on resilient demand
Dec 18, 2024 2:25 AM

Dec 18 (Reuters) - Birkenstock ( BIRK ) beat market

expectations for fourth-quarter revenue on Wednesday, helped by

robust full-price sales of the German footwear maker's pricey

sandals.

With fresh and popular styles becoming a priority for

consumers, particularly in its largest market in the Americas,

Birkenstock's ( BIRK ) sandals and close-toed clogs alike have drawn

loyal customers to its stores, allowing the company to sell more

products at full price.

The company, which debuted on the New York Stock Exchange in

October 2023, invested in expanding its store presence in

markets such as Japan and China, as well as increasing its

manufacturing capacity this year to meet global demand.

Birkenstock ( BIRK ) reported fourth-quarter revenue of 455.8 million

euros ($478.27 million), compared with the average analyst

estimate of 439.2 million euros, according to data compiled by

LSEG.

($1 = 0.9530 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Regeneron Says Libtayo Shows Strong Results in Adjuvant Skin Cancer Trial
Regeneron Says Libtayo Shows Strong Results in Adjuvant Skin Cancer Trial
Jun 2, 2025
07:21 AM EDT, 06/02/2025 (MT Newswires) -- Regeneron (REGN) said Saturday that Libtayo reduced the risk of recurrence or death by 68% in post-surgical high-risk cutaneous squamous cell carcinoma, meeting the phase 3 C-POST trial's primary endpoint. The immunotherapy also cut the risk of locoregional and distant recurrence by 80% and 65%, respectively, the company said. Median disease-free survival was...
Arvinas, Pfizer Report Breast Cancer Treatment Phase 3 Trial Results; Arvinas Shares Down Pre-Bell
Arvinas, Pfizer Report Breast Cancer Treatment Phase 3 Trial Results; Arvinas Shares Down Pre-Bell
Jun 2, 2025
07:21 AM EDT, 06/02/2025 (MT Newswires) -- Arvinas ( ARVN ) and Pfizer ( PFE ) on Saturday reported results from a phase 3 clinical trial of vepdegestrant monotherapy versus fulvestrant in adults with a certain type of advanced or metastatic breast cancer. Vepdegestrant showed a statistically significant and clinically meaningful improvement in progression-free survival among patients with an estrogen...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Campbell's beats third-quarter estimates as eat-at-home trend boosts demand
Campbell's beats third-quarter estimates as eat-at-home trend boosts demand
Jun 2, 2025
(Reuters) -Campbell's Co beat estimates for third-quarter sales and profit on Monday, helped by strong demand for its popular canned food and soups such as Chunky soups and Pace salsa as consumers prefer to eat at home amid an uncertain economy. Fears of a potential recession and price hikes triggered by the imposition of hefty tariffs dented consumer sentiment in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved